These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1663176)

  • 1. [Can fluorodeoxyglucose-positron emission tomography evaluate the functional differentiation of hepatocellular carcinoma].
    Enomoto K; Fukunaga T; Okazumi S; Asano T; Kikuchi T; Yamamoto H; Nagashima T; Isono K; Itoh H; Imazeki K
    Kaku Igaku; 1991 Nov; 28(11):1353-6. PubMed ID: 1663176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET.
    Torizuka T; Tamaki N; Inokuma T; Magata Y; Sasayama S; Yonekura Y; Tanaka A; Yamaoka Y; Yamamoto K; Konishi J
    J Nucl Med; 1995 Oct; 36(10):1811-7. PubMed ID: 7562048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment.
    Okazumi S; Isono K; Enomoto K; Kikuchi T; Ozaki M; Yamamoto H; Hayashi H; Asano T; Ryu M
    J Nucl Med; 1992 Mar; 33(3):333-9. PubMed ID: 1311035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy.
    Torizuka T; Tamaki N; Inokuma T; Magata Y; Yonekura Y; Tanaka A; Yamaoka Y; Yamamoto K; Konishi J
    J Nucl Med; 1994 Dec; 35(12):1965-9. PubMed ID: 7989978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.
    Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC
    Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurements of glucose phosphorylation with FDG and PET are not reduced by dephosphorylation of FDG-6-phosphate.
    Kuwabara H; Gjedde A
    J Nucl Med; 1991 Apr; 32(4):692-8. PubMed ID: 2013809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma.
    Trojan J; Schroeder O; Raedle J; Baum RP; Herrmann G; Jacobi V; Zeuzem S
    Am J Gastroenterol; 1999 Nov; 94(11):3314-9. PubMed ID: 10566736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of 18F-fluoro-2-deoxy-D-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography.
    Miyazawa H; Osmont A; Petit-Taboué MC; Tillet I; Travère JM; Young AR; Barré L; MacKenzie ET; Baron JC
    J Neurosci Methods; 1993 Dec; 50(3):263-72. PubMed ID: 8152238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of glucose metabolism in patients with esophageal cancer by PET: estimation of hexokinase activity in the tumor and usefulness for clinical assessment using 18F-fluorodeoxyglucose].
    Fukunaga T; Enomoto K; Okazumi S; Kikuchi T; Yamamoto H; Koide Y; Isono K
    Nihon Geka Gakkai Zasshi; 1994 May; 95(5):317-25. PubMed ID: 8007937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-to-muscle ratio of 8F-FDG PET for predicting histologic features and recurrence of HCC.
    Baek YH; Lee SW; Jeong YJ; Jeong JS; Roh YH; Han SY
    Hepatogastroenterology; 2015; 62(138):383-8. PubMed ID: 25916068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma?
    Cheung TT; Chan SC; Ho CL; Chok KS; Chan AC; Sharr WW; Ng KK; Poon RT; Lo CM; Fan ST
    Liver Transpl; 2011 Oct; 17(10):1218-25. PubMed ID: 21688383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of [18F]fluorodeoxyglucose accumulation in liver cancer.
    Izuishi K; Yamamoto Y; Mori H; Kameyama R; Fujihara S; Masaki T; Suzuki Y
    Oncol Rep; 2014 Feb; 31(2):701-6. PubMed ID: 24297035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade.
    Wolfort RM; Papillion PW; Turnage RH; Lillien DL; Ramaswamy MR; Zibari GB
    Int Surg; 2010; 95(1):67-75. PubMed ID: 20480845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of selecting a fixed dephosphorylation rate on the estimation of rate constants and rCMRGlu from dynamic [18F] fluorodeoxyglucose/PET data.
    Dhawan V; Moeller JR; Strother SC; Evans AC; Rottenberg DA
    J Nucl Med; 1989 Sep; 30(9):1483-8. PubMed ID: 2788721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET.
    Yamamoto Y; Nishiyama Y; Kameyama R; Okano K; Kashiwagi H; Deguchi A; Kaji M; Ohkawa M
    J Nucl Med; 2008 Aug; 49(8):1245-8. PubMed ID: 18632827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F] fluoro-D-glucose, [1-11C]-acetate and [N-methyl-11C]-choline.
    Salem N; Kuang Y; Wang F; Maclennan GT; Lee Z
    Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):144-56. PubMed ID: 19039303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma.
    Shiomi S; Nishiguchi S; Ishizu H; Iwata Y; Sasaki N; Tamori A; Habu D; Takeda T; Kubo S; Ochi H
    Am J Gastroenterol; 2001 Jun; 96(6):1877-80. PubMed ID: 11419843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of ¹⁸F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma.
    Pant V; Sen IB; Soin AS
    Nucl Med Commun; 2013 Aug; 34(8):749-57. PubMed ID: 23689586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors.
    Song JY; Lee YN; Kim YS; Kim SG; Jin SJ; Park JM; Choi GS; Chung JC; Lee MH; Cho YH; Choi MH; Kim DC; Choi HJ; Moon JH; Lee SH; Jeong SW; Jang JY; Kim HS; Kim BS
    Nucl Med Commun; 2015 Apr; 36(4):319-27. PubMed ID: 25564069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET.
    Piert M; Koeppe RA; Giordani B; Berent S; Kuhl DE
    J Nucl Med; 1996 Feb; 37(2):201-8. PubMed ID: 8667045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.